This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pamnani, M. B. Articles by Haddy, F. J. Search for Related Content PubMed PubMed Citation Articles by Pamnani, M. B. Articles by Haddy, F. J.

Hypertension, Vol 18, 316-324, Copyright © 1991 by American Heart Association

ARTICLES

Effects of three sodium-potassium adenosine triphosphatase inhibitors

MB Pamnani, S Chen, HJ Bryant, JF Schooley Jr, DC Eliades, CM Yuan and FJ Haddy
Department of Physiology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799.

Reports from several laboratories suggest the presence of an ouabainlike compound in plasma and various animal tissues, particularly during acute volume expansion and in low-renin hypertension. It has been hypothesized that this compound, through inhibition of the Na(+)- K+ pump, can constrict blood vessels, enhance vasoconstriction in response to agonists, increase cardiac contractility, raise blood pressure, and cause natriuresis/diuresis and therefore is implicated in the pathophysiology of the low-renin, volume-expanded type of hypertension. However, so far, only two steroid Na(+)-K+ pump inhibitors (namely, a bufodienolide derivative [resibufogenin], obtained from toad skin and plasma and a factor with the same carbon, oxygen, and hydrogen content as ouabain obtained from the plasma of volume-expanded humans) have been purified and structurally characterized. To determine whether such endogenous Na(+)-K+ pump inhibitors can in fact produce the above effects on the cardiovascular and renal systems, we infused commercially available bufalin (aglycone, identical to resibufogenin except for one H+), ouabain, and ouabagenin (aglycone) at equimolar doses in normotensive rats. Relative to ouabain, bufalin produced significantly greater dose-dependent increases in blood pressure, left ventricular rate of pressure change, heart rate, and excretion of urinary volume and sodium. Ouabagenin was without effect on any of these parameters. These data indicate that a Na(+)-K+ pump inhibitor can cause an increase in blood pressure despite potent diuretic and natriuretic effects and that, in rats, bufalin is much more potent in this respect than ouabain or ouabagenin.

This article has been cited by other articles:

				O. V. Fedorova, D. E. Anderson, E. G. Lakatta, and A. Y. Bagrov Interaction of NaCl and behavioral stress on endogenous sodium pump ligands in rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R352 - R358. [Abstract] [Full Text] [PDF]

				R. I. Dmitrieva, A. Y. Bagrov, E. Lalli, P. Sassone-Corsi, D. M. Stocco, and P. A. Doris Mammalian Bufadienolide Is Synthesized From Cholesterol in the Adrenal Cortex by a Pathway That Is Independent of Cholesterol Side-Chain Cleavage Hypertension, September 1, 2000; 36(3): 442 - 448. [Abstract] [Full Text] [PDF]

				S. Linton and M. O'Donnell Contributions of K+:Cl- cotransport and Na+/K+-ATPase to basolateral ion transport in malpighian tubules of Drosophila melanogaster J. Exp. Biol., January 6, 1999; 202(11): 1561 - 1570. [Abstract] [PDF]

				S.-W. Wang, Y.-C. Chiao, S.-C. Tsai, C.-C. Lu, J.-J. Chen, H.-C. Shih, Y.-H. Chen, H. Lin, C.-M. Hwu, and P. S. Wang Inhibition of Bufalin on Pituitary and Testicular Function in Rats J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 528 - 532. [Abstract] [Full Text]

				E. D. Murray Jr., W. J. Wechter, D. Kantoci, W.-H. Wang, T. Pham, D. D. Quiggle, K. M. Gibson, D. Leipold, and B. M. Anner Endogenous Natriuretic Factors 7: Biospecificity of a Natriuretic gamma -Tocopherol Metabolite LLU-alpha J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 657 - 662. [Abstract] [Full Text]

				A. R. Patel, T. Kurashina, J. P. Granger, and K. A. Kirchner Acute Na+,K+-ATPase Inhibition With Bufalin Impairs Pressure Natriuresis in the Rat Hypertension, March 1, 1996; 27(3): 668 - 671. [Abstract] [Full Text]